Regenerative medicine company AVITA Medical (ASX:AVH) has announced that the US FDA has approved its premarket approval supplement for the use of the RECELL System to treat full-thickness skin defects.
AVITA Medical announces US approval of RECELL for full thickness skin defects
June 8, 2023 Australian Biotech
Latest Video
New Stories
-
‘Game-changer’ clinical trial launches for Australia’s second-deadliest cancer
April 29, 2025 - - Latest News -
These system-shifting therapies come along every few years, but this is different
April 29, 2025 - - Latest News -
Culture review delivers a scathing assessment of New Zealand's Pharmac
April 29, 2025 - - Latest News -
Pfizer-commissioned survey reveals rising GP concerns over medical misinformation
April 29, 2025 - - Latest News -
New survey confirms significant interest in accessing weight loss therapies
April 28, 2025 - - Latest News -
Medicines Australia announces appointment of communications director
April 28, 2025 - - Latest News -
Recce Pharmaceuticals enters research and development agreement with US defence
April 28, 2025 - - Australian Biotech